(Adnkronos) - “Nello studio Quasar, che ha valutato l’efficacia e la sicurezza di guselkumab nei pazienti con colite ulcerosa moderatamente grave, è stato dimostrato come, dopo un anno di trattamento, fino al 35% dei pazienti raggiungevano un endpoint molto importante che era quello del mucosal healing”. Queste le parole di Alessandro Armuzzi, professore di gastroenterologia presso l’istituto Humanitas di Rozzano, in occasione del Congresso dell’Italian Group of Inflammatory Bowel Disease (Ig-Ibd), in svolgimento a Riccione dal 28 al 30 novembre dedicato alle malattie infiammatorie croniche intestinali - Mici.
Category
🗞
NewsTranscript
00:00In the Quasar study, which evaluated the efficacy and safety of Guzelcumab in patients affected by moderately serious colitis ulcerosa,
00:12it was shown that, after a year of treatment, up to 35% of patients with colitis ulcerosa reached a very important endpoint, which was that of mucosal healing.
00:23Endoscopic remission, in addition to that clinic, and even more than that clinic, is very important to define the long-term outcomes of colitis ulcerosa,
00:32as it has been shown that up to 70% of patients in the long term who reach an endoscopic remission remain free from recidivism.
00:42The equally important aspect is that this result has been documented to be significantly positive,
00:50also in patients who had previously failed advanced therapies, and not only in patients naive to biopharmaceuticals.